Crystal structure of the human 5-HT1B serotonin receptor bound to an inverse agonist

Wanchao Yin,X. Edward Zhou,Dehua Yang,Parker W. de Waal,Meitian Wang,Antao Dai,Xiaoqing Cai,Chia-Ying Huang,Ping Liu,Xiaoxi Wang,Yanting Yin,Bo Liu,Yu Zhou,Jiang Wang,Hong Liu,Martin Caffrey,Karsten Melcher,Yechun Xu,Ming-Wei Wang,H. Eric Xu,Yi Jiang
DOI: https://doi.org/10.1038/s41421-018-0009-2
IF: 38.079
2018-03-13
Cell Discovery
Abstract:Abstract5-hydroxytryptamine (5-HT, also known as serotonin) regulates many physiological processes through the 5-HT receptor family. Here we report the crystal structure of 5-HT1B subtype receptor (5-HT1BR) bound to the psychotropic serotonin receptor inverse agonist methiothepin (MT). Crystallization was facilitated by replacing ICL3 with a novel optimized variant of BRIL (OB1) that enhances the formation of intermolecular polar interactions, making OB1 a potential useful tool for structural studies of membrane proteins. Unlike the agonist ergotamine (ERG), MT occupies only the conserved orthosteric binding pocket, explaining the wide spectrum effect of MT on serotonin receptors. Compared with ERG, MT shifts toward TM6 and sterically pushes residues W3276.48, F3306.50 and F3316.51 from inside the orthosteric binding pocket, leading to an outward movement of the extracellular end and a corresponding inward shift of the intracellular end of TM6, a feature shared by other reported inactive G protein-coupled receptor (GPCR) structures. Together with the previous agonist-bound serotonin receptor structures, the inverse agonist-bound 5-HT1BR structure identifies a basis for the ligand-mediated switch of 5-HT1BR activity and provides a structural understanding of the inactivation mechanism of 5-HT1BR and some other class A GPCRs, characterized by ligand-induced outward movement of the extracellular end of TM6 that is coupled with inward movement of the cytoplasmic end of this helix.
cell biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to reveal the crystal structure of the serotonin receptor 5 - HT1B subtype (5 - HT1BR) bound to its inverse agonist methiothepin (MT), in order to understand its molecular recognition mechanism and the ligand - mediated inhibition mechanism of 5 - HT1BR activity. Specifically, the research aims to: 1. **Provide the first structure of 5 - HT1BR bound to an inverse agonist**: This is the first time that the structure of 5 - HT1BR bound to an inverse agonist has been resolved, filling the current gap in the understanding of the 5 - HT1BR structure, especially the information on how the inverse agonist interacts with the receptor. 2. **Explore the inactivation mechanism of 5 - HT1BR**: By comparing the conformational changes of 5 - HT1BR when bound to agonists and inverse agonists, the researchers hope to elucidate the specific mechanism by which 5 - HT1BR transitions from the active state to the inactive state. This includes the phenomenon that TM6 (transmembrane helix 6) moves outward at the extracellular end and inward at the intracellular end, a feature that has also been reported in other known inactive - state G - protein - coupled receptor (GPCR) structures. 3. **Optimize membrane protein crystallization techniques**: In order to obtain high - quality crystals, the researchers developed an improved BRIL fusion partner (OB1) to improve the crystallization properties of 5 - HT1BR. This technological advancement is of great significance for future structural studies of other GPCRs. 4. **Guide structure - based drug design**: By resolving the structure of 5 - HT1BR bound to MT, the researchers hope to provide a structural basis for the development of more effective and more specific 5 - HT1BR antagonists or inverse agonists, which may be used to treat various diseases such as depression and migraine. In summary, this paper not only provides important structural biology data, but also provides a new perspective for understanding the functional mechanism of 5 - HT1BR and its application in drug development.